Astellas Withdraws Izervay’s European Approval Filing

 
• By Lisa Takagi

Decision contrasts with successful journey in the US, where it was approved with Fast Track designation in 2023. Astellas says its considering “every potential action” to bring GA drug to patients in Europe.

Izervay's European approval was withdrawn by Astellas after its interactions with CHMP. (Shutterstock)

More from EU CHMP

More from Product Reviews